News Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 10/04/2026 BST			5-day change	1st Jan Change
238.46 ^USD	-1.18%		-1.88%	+15.23%

04-10	S&P 500 Posts Weekly Gain Ahead of Iran Peace Talks, Earnings	MT
04-10	US earnings season set to test war-rattled stocks	RE

All News

04-10	S&P 500 Posts Weekly Gain Ahead of Iran Peace Talks, Earnings	MT
04-10	US earnings season set to test war-rattled stocks	RE
04-10	Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision	BU
04-10	Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IoL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision	CI
04-10	Wall St Week Ahead-US earnings season set to test war-rattled stocks	RE
04-10	Take Five: Eyes on Islamabad	RE
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-09	Terumo Deepens Costa Rica Investment Amid Medtech Growth	MT
04-07	Johnson & Johnson Launches Varipulse Pro Platform in Europe	CI
04-07	Hologic, Inc. Announces the Appointment of José E. Almeida as Chief Executive Officer, Effective April 7, 2026	CI
04-07	Johnson & Johnson Launches Varipulse Pro in Europe	MT
04-07	Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe	BU
04-07	Citigroup Adjusts Price Target on Johnson & Johnson to $285 From $274, Maintains Buy Rating	MT
04-07	Guggenheim Adjusts Price Target on Johnson & Johnson to $244 From $240, Maintains Buy Rating	MT
04-06	Johnson & Johnson named to Fortune's 2026 America's Most Innovative Companies list; The company's dedication to advancing solutions for the world's most pressing health challenges has once again earned it a place on this annual ranking.	AQ
04-06	Hologic Chairman, CEO Steve MacMillan to Step Down When Takeover Closes	DJ
04-02	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
04-02	Change in Orion Group Executive Team as of 8 April 2026, Berkeley Vincent appointed Executive Vice President, Innovative Medicines	AQ
04-02	Harmony Biosciences Holdings, Inc. Announces Management Changes	CI
04-02	Johnson & Johnson Announces Permanent Billing Code For INLEXZO Gemcitabine Intravesical System For Bladder Cancer Treatment	CI
04-02	US Set to Impose 100% Tariffs on Some Drug Imports	MT
04-01	Trump administration readies new tariffs on select drugmakers, Bloomberg News reports	RE
04-01	Orion Corporation Appoints Berkeley Vincent as Executive Vice President, Innovative Medicines and A Member of the Orion Executive Team as of 8 April 2026	CI
04-01	Orion appoints new head of Innovative Medicines	FW
04-01	J&J - announced permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Inlexzo is now in effect	RE